The study shows semaglutide's cardiovascular benefits are more closely tied to attained dose than weight loss, challenging existing treatment assumptions. Evaxion A/S (“Evaxion”), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results